4-o-tolyl-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester | 951167-02-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 4-o-tolyl-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester
• 英文别名: 1-tert-butyl 4-o-tolyl-5,6-dihydro-2H-pyridine-1,3-dicarboxylate；4-(2-methylphenyl)-1-[(2-methylpropan-2-yl)oxycarbonyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid
• CAS: 951167-02-5
• 化学式: C₁₈H₂₃NO₄
• 分子量: 317.385
• InChiKey: BVPBHSHQHBHXCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-o-tolyl-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 在 [Ru(OAc)2((S)-(6-MeO-2-Naphthyl)-MeOBIPHEP)] 氢气 、 三乙胺 、 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 甲基叔丁基醚 、 水 为溶剂， 80.0 ℃ 、4.0 MPa 条件下， 反应 42.0h， 以80%的产率得到(+)-(cis)-4-o-tolyl-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester
  参考文献：
  名称：

  Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids

  摘要：

  本发明涉及一种通过对下列方案进行对映选择性氢化反应，制备高对映异构体和对映选择性的顺式取代的环状β-芳基或杂芳基羧酸衍生物的方法，其中X、Ar、n和m在此定义，并且包括相应的盐。

  公开号：

  US20070232653A1

文献信息

• PIPERAZINE AMIDE DERIVATIVES
  申请人：Dehmlow Henrietta

  公开号：US20090048264A1

  公开（公告）日：2009-02-19

  The invention is concerned with novel piperazine amide derivatives of formula (I) wherein R 1 to R 11 , W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

  这项发明涉及一种新型哌嗪酰胺衍生物，其化学式为（I），其中R1至R11、W、X和Y如描述和索赔中定义，并且其生理上可接受的盐。这些化合物能够结合到LXRα和LXRβ，并可用作药物。
• Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety
  申请人：Grundschober Christophe

  公开号：US20070232652A1

  公开（公告）日：2007-10-04

  The present invention relates to trans-derivatives of formula wherein R 1 , R 2 , R 3 , and the dotted line are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.

  本发明涉及公式中的转衍生物，其中R1、R2、R3和虚线如本文所定义，并且其药用可接受酸盐。公式I的化合物是良好的5-羟色胺转运体抑制剂（SERT抑制剂），同时它们对NK-1受体也具有良好的活性（双重效应）。由于其作为SERT抑制剂的功效，本发明中的化合物特别适用于治疗中枢神经系统疾病和精神疾病，特别是在治疗或预防抑郁状态和/或焦虑症的治疗中。
• Piperazine amide derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US08288541B2

  公开（公告）日：2012-10-16

  The invention is concerned with novel piperazine amide derivatives of formula (I) wherein R1 to R11, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

  这项发明涉及公式(I)中的新型哌嗪酰胺衍生物，其中R1至R11、W、X和Y如说明书和权利要求中所定义，以及其生理学上可接受的盐。这些化合物与LXR alpha和LXR beta结合，可用作药物。
• SEROTONIN TRANSPORTER (SERT) INHIBITORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY
  申请人：Grundschober Christophe

  公开号：US20110105561A1

  公开（公告）日：2011-05-05

  The present invention relates to trans-derivatives of formula wherein R 1 , R 2 , R 3 , and the dotted line are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.

  本发明涉及公式I的转衍生物，其中R1、R2、R3和点线的定义如本文所述，并且其药学上可接受的酸加成盐。公式I的化合物是良好的5-羟色胺转运体（SERT）抑制剂，同时它们对NK-1受体也具有良好的活性（双重作用）。由于它们作为SERT抑制剂的功效，本发明中的化合物特别适用于治疗中枢神经系统疾病和精神障碍，特别是用于治疗或预防抑郁状态和/或治疗焦虑症。
• PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS
  申请人：Bachmann Stephan

  公开号：US20110105758A1

  公开（公告）日：2011-05-05

  The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme wherein X, Ar, n, and m are defined hereinand corresponding salts thereof.

  本发明涉及一种通过对以下图示反应进行对映选择性氢化，以高对映异构体和对映选择性制备顺式取代的环状β-芳基或杂芳基羧酸衍生物的方法：其中X，Ar，n和m在此定义，并对应的盐。